The largest GWAS study to date provides evidence that despite a high correlation with MDD, PPD may have unique genetic components.
A new study from Hantsoo and colleagues asks whether SRI treatment affects the levels of neuroactive steroids modulating GABA-A receptors.
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
This article focuses on how GABA-ergic neurotransmitter systems may modulate the interaction between reproductive steroid and sex steroid systems, and sheds light on the role allopregnanolone may play in medicating vulnerability to depression.Â
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors. Â We saw the preliminary [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â This drug was initially under [...]
SAGE-547 (SAGE Therapeutics) is a new drug, an allosteric modulator of GABAA receptors, which is currently under investigation for the treatment of refractory seizure disorders. Â It turns out that SAGE-547 may also be useful for [...]
